Key facts
- This page summarizes Douglas E. Williams's Form 4 filing for Ovid Therapeutics Inc. (OVID).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 May 2021, 21:04.
Douglas E. Williams - 17 May 2021 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)
- Reporting relationship
- Director
- Issuer ticker
- OVID
- Reported as of
- 17 May 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 18 May 2021, 21:04:25 UTC
- Next SEC filing
- 21 Jan 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Danielle Mann for Doug Williams by PoA
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas E. Williams filed Form 4 for Ovid Therapeutics Inc. (OVID) on 18 May 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OVID
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,750
- Change %
- Price
- $0.000000
- Shares after
- 1,750
- Date
- 17 May 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,750
- Exercise price
- $3.67
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option will vest in full on June 5, 2021, subject to the Reporting Person's continuous service through such vesting date.